GFAP and Alzheimer disease: In conjunction with GFAP, it labels reactive astrocytes and exerts neurotoxicity in neurodegenerative diseases, such as Alzheimer’s disease (AD), ALS, multiple sclerosis (MS), and Parkinson’s disease (PD), as well as in infectious diseases and spinal cord injury [44,45,46,47].